RecruitingNCT06192576
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
Studying Acid sphingomyelinase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Olipudase alfa(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2029
Study locations (5)
- Ann and Robert H Lurie Children's Hospital of Chicago- Site Number: 001002, Chicago, Illinois, United States
- Children's Hospital Medical Center- Site Number: 001003, Cincinnati, Ohio, United States
- Nationwide Children's Hospital - PIN- Site Number : 1001-1, Columbus, Ohio, United States
- Pulse InfoFrame US Inc.- Site Number: 001001, Philadelphia, Pennsylvania, United States
- Dell Children's Medical Center- Site Number : 1001-2, Austin, Texas, United States
Collaborators
Pulse Infoframe Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06192576 on ClinicalTrials.govOther trials for Acid sphingomyelinase deficiency
Additional recruiting or active studies for the same condition.